SAMUEL D ISALY
CIK 1055949 · last filed 2018-01-04
SAMUEL D ISALY is a corporate insider who has filed 36 SEC Form 4 insider transactions across 23 companies since 2008. The most recent filing shows the insider sold $37.7M of PIRS on Jan 4, 2018. Across all open-market trades the lifetime net is −$250.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.10B across reported positions. 207 SEC filings were submitted jointly with ORBIMED ADVISORS LLC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.10B
Companies
23
Total Filings
36
Lifetime Open-Market Net
-$250.26M
Filer Profile
Reported Address
601 LEXINGTON AVENUE54TH FLOOR
NEW YORK, NY 10022
Related Filers
ORBIMED ADVISORS LLC — 207 joint filings, latest 2018-01-19
OrbiMed Capital GP III LLC — 61 joint filings, latest 2018-01-04
OrbiMed Capital GP IV LLC — 52 joint filings, latest 2017-11-20
OrbiMed Capital GP V LLC — 25 joint filings, latest 2017-12-12
ORBIMED CAPITAL GP II LLC — 16 joint filings, latest 2013-09-26
ORBIMED CAPITAL LLC — 14 joint filings, latest 2012-02-15
OrbiMed Capital GP VI LLC — 13 joint filings, latest 2018-01-12
Pacira BioSciences, Inc. — 6 joint filings, latest 2012-03-13
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | 10%+ Owner | 68,759 | $13.60 | $935.1K | -$40.22M | 2 | 2018-01-04 |
| Loxo Oncology, Inc. (LOXO) Delisted | Director | 1,191,000 | — | — | -$109.49M | 3 | 2017-11-27 |
| X4 Pharmaceuticals, Inc (ASNS) Delisted | 10%+ Owner | 33 | $0.08 | $3 | $0 | 1 | 2017-11-20 |
| Roka BioScience, Inc. (ROKA) Delisted | 10%+ Owner | 0 | — | — | -$1.44M | 2 | 2017-10-05 |
| BOLD | 10%+ Owner | 4,806,638 | $2.83 | $13.60M | -$335.2K | 1 | 2017-09-11 |
| GKOS | Director | 1,628,111 | $167.25 | $272.30M | -$89.00M | 2 | 2017-08-17 |
| KALA | 10%+ Owner | 951 | $0.57 | $544 | $14.37M | 1 | 2017-07-27 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | 3,298,516 | $64.97 | $214.30M | $0 | 1 | 2017-07-26 |
| ASND | Director | 6,149,377 | $263.51 | $1.62B | $15.00M | 1 | 2017-03-28 |
| CRVS | Director | 5,379,349 | $12.91 | $69.45M | $464.3K | 3 | 2016-06-27 |
| OTONOMY, INC. (OTIC) Delisted | Director | 1,953,300 | $0.08 | $150.4K | -$17.21M | 1 | 2015-11-24 |
| Sientra, Inc. (SIEN) Delisted | 10%+ Owner | 1,988 | $0.17 | $346 | -$14.36M | 1 | 2015-10-09 |
| Sierra Oncology, Inc. (DNAI) Delisted | Director | 1,725,790 | — | — | $8.93M | 1 | 2015-07-21 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Director | 1,656,582 | $19.00 | $31.48M | $0 | 2 | 2014-08-11 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | Director | 27,531 | — | — | $2.30M | 2 | 2013-01-29 |
| SUPN | 10%+ Owner | 0 | $41.64 | $0 | -$6.19M | 1 | 2012-12-19 |
| GNOM | 10%+ Owner | 730,535 | $62.22 | $45.45M | -$9.91M | 1 | 2012-07-13 |
| PCRX | 10%+ Owner | 2,546,100 | $25.36 | $64.57M | -$1.40M | 1 | 2012-02-29 |
| CCXI | 10%+ Owner | 908,509 | $12.32 | $11.19M | $0 | 1 | 2012-02-15 |
| AMRN | Director | 345,455 | $13.80 | $4.77M | -$1.72M | 1 | 2011-03-07 |
| NxStage Medical, Inc. (NXTM) Delisted | Director | 4,152,700 | — | — | -$1.67M | 2 | 2010-09-09 |
| ALBIREO PHARMA, INC. (BIOD) Delisted | Director | 50,430 | — | — | -$282.8K | 1 | 2009-06-11 |
| ATHERSYS, INC / NEW (ATHX) Delisted | Director | 137,920 | $0.01 | $1.9K | $1.91M | 2 | 2008-05-23 |
Recent Filings
36 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-01-04 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Sell (S) | −5,128,860 | -$37.70M | EDGAR |
| 2017-12-20 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Mixed | — | -$1.60M | EDGAR |
| 2017-11-27 | Loxo Oncology, Inc. (LOXO) Delisted | Sell (S) | −801,000 | -$60.08M | EDGAR |
| 2017-11-20 | X4 Pharmaceuticals, Inc (ASNS) Delisted | Conv (C) | +5,606,898 | $15.00M | EDGAR |
| 2017-11-20 | Loxo Oncology, Inc. (LOXO) Delisted | Sell (S) | −810,000 | -$60.15M | EDGAR |
| 2017-10-05 | Roka BioScience, Inc. (ROKA) Delisted | Sell (S) | −604,851 | -$411.3K | EDGAR |
| 2017-10-02 | Roka BioScience, Inc. (ROKA) Delisted | Sell (S) | −1,424,028 | -$1.03M | EDGAR |
| 2017-09-11 | BOLD | Mixed | — | -$109.8K | EDGAR |
| 2017-08-17 | GKOS | Sell (S) | −975,000 | -$36.98M | EDGAR |
| 2017-07-27 | KALA | Mixed | +7,125,837 | $14.37M | EDGAR |
Showing 1–10 of 36
Page 1 of 4
Next
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.